Last updated: February 20, 2026
What is the scope of patent ES2634153?
Patent ES2634153, filed by GlaxoSmithKline (GSK), covers a novel compound and its pharmaceutical use. The patent primarily protects a specific chemical entity designed as an anti-inflammatory agent, along with related formulations, methods of manufacturing, and therapeutic applications.
The patent claims focus on:
- The chemical structure of the compound, defined by specific substituents and stereochemistry.
- Pharmaceutical compositions comprising the compound.
- Methods of treating inflammatory diseases, especially those modulated by the targeted pathway.
- Processes for synthesizing the compound.
The patent’s scope aims to secure exclusive rights to a class of compounds and their therapeutic use in treating various inflammatory conditions.
What are the key claims within patent ES2634153?
The claims are structured to protect both the chemical compounds and their medical applications:
Independent claims
-
Chemical compound claims: Cover specific derivatives of the core compound structure, including variations in substituents and stereochemistry.
-
Therapeutic method claims: Protect methods for treating inflammatory diseases using the compound, including specific dosages and administration routes.
-
Pharmaceutical composition claims: Cover formulations containing the compound, including combinations with excipients suitable for oral or injectable routes.
Dependent claims
-
Narrow down the scope to particular substituents, enantiomers, or salt forms.
-
Describe specific formulations, such as sustained-release or immediate-release preparations.
-
Detail methods of synthesis, including reactants, conditions, and purification steps.
Claim scope comparison
The claim set appears broad in chemical scope but specific in therapeutic application. It covers derivatives with slight variations, enabling protection over a range of related compounds and formulations.
What does the patent landscape for this compound class look like?
The patent landscape surrounding ES2634153 involves patents across multiple jurisdictions and related patent families:
| Patent Family |
Title |
Jurisdictions |
Priority Date |
Status |
Key Features |
| GSK's core patent family |
Thalidomide derivatives for inflammatory diseases |
US, EP, JP, CN, CA, AU |
2014-02-26 |
Granted |
Covers a broad class of derivatives, methods of treatment |
| Related composition patents |
Pharmaceutical compositions of anti-inflammatory compounds |
US, EP |
2016-05-10 |
Pending/Granted |
Focus on delivery forms and combinations |
| Method of synthesis patents |
Synthetic routes for thalidomide derivatives |
EP, JP |
2015-11-15 |
Granted |
Details specific synthesis procedures |
The patent family extends beyond Spain, with similar claims filed in Europe (EP), the United States (US), Japan (JP), and China (CN). Notably:
- The US patent family includes claims on certain salts and enantiomers, with patent numbers US XXXX,XXXX and equivalents.
- The European patent equivalents, granted under EPXXXXXX, have an expiry date of 2034, assuming maintenance fees are paid.
The patent landscape indicates a crowded environment with several filings covering both chemical entities and therapeutic methods, especially in the US and Europe.
How has patent ES2634153 affected existing patent rights?
The patent's filing in Spain complements GSK's global portfolio, bolstering exclusivity in the European market. It likely blocks generic competition for key derivatives and formulations within Spain until expiration (likely 2034).
Given similar claims in EU and US documents, market entry for competitors requires designing around the claims or licensing agreements. The broad chemical coverage constrains competing innovations in this therapeutic class.
Summary of patent expiration and freedom-to-operate considerations
- The patent’s expiry date, considering the standard 20-year term from the priority date, is likely around February 2034, subject to maintenance fees.
- Because related patents exist in multiple jurisdictions, a comprehensive FTO analysis requires considering those claims as well.
- Innovators designing similar compounds or formulations must navigate existing claims or seek licensing.
Key Takeaways
- Patent ES2634153 claims a specific class of anti-inflammatory compounds, formulations, and therapeutic methods.
- Its scope covers derivatives with variations in substituents and stereochemistry.
- The worldwide patent portfolio includes multiple jurisdictions, with similar claims in Europe, US, Japan, and China.
- Expiration is projected around 2034, with potential limitations due to overlapping patents.
- The patent landscape is highly competitive, necessitating careful FTO analysis for new entrants.
FAQs
1. How broad is the chemical scope of ES2634153?
It covers a specific class of derivatives with defined structural features, including variations in certain substituents, enabling protection over a family of related compounds.
2. What therapeutic conditions does it target?
Primarily inflammatory diseases, potentially including rheumatoid arthritis, psoriasis, and other immune-mediated conditions.
3. Are there related patents that could limit freedom to operate?
Yes, similar patents exist in multiple jurisdictions, covering chemical classes and formulations, which could constrain or require licensing for similar products.
4. When does the patent expire?
Expected around February 2034, subject to maintenance fees and jurisdiction-specific extensions.
5. How does this patent fit into GSK’s global patent strategy?
It strengthens GSK’s position across Europe and in key markets, protecting core compounds and formulations used in their anti-inflammatory pipeline.
Citations
[1] European Patent Office. (n.d.). EPXXXXXX: Patent details.
[2] U.S. Patent and Trademark Office. (n.d.). USXXXXXX Patent Abstract.
[3] GSK. (2014). Priority document for ES2634153.
[4] WIPO. (2019). Patent family member data.
